Key Points
- CFO Gerardo Hernandez sold 7,236 shares on March 4 at an average price of $147.21 for about $1.065 million, reducing his holding by 33% to 14,689 shares valued near $2.16 million.
- TransMedics (TMDX) has a market cap of about $5.06 billion, a P/E of 30.13 and a 52‑week range of $62.07–$156, with a Wall Street consensus of “Moderate Buy” and an average target price of $150.67 after recent upward revisions.
TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) insider Nicholas Corcoran sold 2,966 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $412,629.92. Following the transaction, the insider directly owned 29,831 shares in the company, valued at approximately $4,150,088.72. The trade was a 9.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
TransMedics Group Trading Down 1.5%
TransMedics Group stock traded down $2.23 during midday trading on Thursday, hitting $145.43. 60,903 shares of the stock were exchanged, compared to its average volume of 797,657. TransMedics Group, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $156.00. The stock has a market capitalization of $4.99 billion, a price-to-earnings ratio of 29.68 and a beta of 1.98. The stock's 50-day simple moving average is $134.97 and its 200 day simple moving average is $126.78. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06.
Analysts Set New Price Targets
Several analysts have recently commented on TMDX shares. Needham & Company LLC lifted their price target on shares of TransMedics Group from $166.00 to $174.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Canaccord Genuity Group increased their price objective on TransMedics Group from $147.00 to $148.00 and gave the stock a "buy" rating in a research report on Wednesday, December 17th. Oppenheimer lifted their target price on TransMedics Group from $150.00 to $175.00 and gave the company an "outperform" rating in a research report on Wednesday, February 25th. Morgan Stanley upped their price target on TransMedics Group from $123.00 to $135.00 and gave the company an "equal weight" rating in a research note on Tuesday, December 2nd. Finally, Piper Sandler raised their price objective on TransMedics Group from $140.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $150.67.
Get Our Latest Analysis on TransMedics Group
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of TransMedics Group by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company's stock valued at $404,549,000 after buying an additional 9,650 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company's stock valued at $119,997,000 after acquiring an additional 113,817 shares during the period. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company's stock valued at $117,506,000 after acquiring an additional 322,353 shares during the period. Geode Capital Management LLC grew its position in TransMedics Group by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company's stock valued at $99,339,000 after acquiring an additional 2,903 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company's stock worth $71,291,000 after purchasing an additional 223,409 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.
TransMedics currently markets two commercially available OCS platforms.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
